v3.22.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Operating expenses:        
Research and development $ 29,756 $ 21,091 $ 69,822 $ 49,989
General and administrative 11,515 10,549 38,984 29,211
Total operating expenses 41,271 31,640 108,806 79,200
Other expense 114 503 825 352
Loss before benefit for income taxes (41,385) (32,143) (109,631) (79,552)
Benefit for income taxes 0 (367) (72) (279)
Net loss $ (41,385) $ (31,776) $ (109,559) $ (79,273)
Net loss per common share - basic (in dollars per share) $ (0.36) $ (0.32) $ (1.02) $ (0.94)
Net loss per common share - diluted (in dollars per share) $ (0.36) $ (0.32) $ (1.02) $ (0.94)
Weighted-average common shares outstanding – basic (in shares) 115,025,191 97,920,460 107,447,745 84,413,511
Weighted-average common shares outstanding – diluted (in shares) 115,025,191 97,920,460 107,447,745 84,413,511

Source